250 related articles for article (PubMed ID: 24502453)
1. Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective.
Eckstein N; Röper L; Haas B; Potthast H; Hermes U; Unkrig C; Naumann-Winter F; Enzmann H
J Exp Clin Cancer Res; 2014 Feb; 33(1):15. PubMed ID: 24502453
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitors in cancers: Treatment optimization - Part I.
Combarel D; Dousset L; Bouchet S; Ferrer F; Tetu P; Lebbe C; Ciccolini J; Meyer N; Paci A
Crit Rev Oncol Hematol; 2024 Jul; 199():104384. PubMed ID: 38762217
[TBL] [Abstract][Full Text] [Related]
3. [Protein tyrosine kinase inhibitors in cancer therapy].
Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
[TBL] [Abstract][Full Text] [Related]
4. FGFR-TKI resistance in cancer: current status and perspectives.
Yue S; Li Y; Chen X; Wang J; Li M; Chen Y; Wu D
J Hematol Oncol; 2021 Feb; 14(1):23. PubMed ID: 33568192
[TBL] [Abstract][Full Text] [Related]
5. Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy.
Bronte G; Bronte E; Novo G; Pernice G; Lo Vullo F; Musso E; Bronte F; Gulotta E; Rizzo S; Rolfo C; Silvestris N; Bazan V; Novo S; Russo A
Expert Opin Drug Saf; 2015 Feb; 14(2):253-67. PubMed ID: 25494575
[TBL] [Abstract][Full Text] [Related]
6. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
Hojjat-Farsangi M
J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors.
Natoli C; Perrucci B; Perrotti F; Falchi L; Iacobelli S;
Curr Cancer Drug Targets; 2010 Aug; 10(5):462-83. PubMed ID: 20384577
[TBL] [Abstract][Full Text] [Related]
8. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Riccaboni M; Bianchi I; Petrillo P
Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
[TBL] [Abstract][Full Text] [Related]
9. Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
Fernandez S; Desplat V; Villacreces A; Guitart AV; Milpied N; Pigneux A; Vigon I; Pasquet JM; Dumas PY
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336846
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinases as targets in cancer therapy - successes and failures.
Traxler P
Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis.
Cepero V; Sierra JR; Giordano S
Curr Pharm Des; 2010; 16(12):1396-409. PubMed ID: 20166985
[TBL] [Abstract][Full Text] [Related]
12. Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Sakle NS; More SA; Dhawale SA; Mokale SN
Curr Drug Discov Technol; 2020; 17(5):585-615. PubMed ID: 31393251
[TBL] [Abstract][Full Text] [Related]
13. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
14. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
Steeghs N; Nortier JW; Gelderblom H
Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
Hartmann JT; Haap M; Kopp HG; Lipp HP
Curr Drug Metab; 2009 Jun; 10(5):470-81. PubMed ID: 19689244
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.
Lee CC; Shiao HY; Wang WC; Hsieh HP
Expert Opin Investig Drugs; 2014 Oct; 23(10):1333-48. PubMed ID: 24921970
[TBL] [Abstract][Full Text] [Related]
17. Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment.
Giordani E; Zoratto F; Strudel M; Papa A; Rossi L; Minozzi M; Caruso D; Zaccarelli E; Verrico M; Tomao S
Curr Cancer Drug Targets; 2016; 16(2):175-85. PubMed ID: 26278713
[TBL] [Abstract][Full Text] [Related]
18. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.
Matos I; Elez E; Capdevila J; Tabernero J
Expert Opin Emerg Drugs; 2016 Sep; 21(3):267-82. PubMed ID: 27578253
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.
Chen MH; Kerkelä R; Force T
Circulation; 2008 Jul; 118(1):84-95. PubMed ID: 18591451
[No Abstract] [Full Text] [Related]
20. Role of tyrosine kinase inhibitors in cancer therapy.
Arora A; Scholar EM
J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]